Trials / Recruiting
RecruitingNCT06313567
Metronomic Capecitabine in Stage III Gastric Cancer
Metronomic Capecitabine as Adjuvant Therapy in Stage III Gastric Cancer: a Multicentre, Open-label, Parallel-group, Randomised, Controlled, Phase 3 Trial
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 722 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out whether treatment with metronomic capecitabine will improve the survival of gastric cancer patients with stage III who had received standard treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Metronomic capecitabine group | 500 mg/m2 body surface area twice daily for 1 year; metronomic capecitabine group |
| OTHER | Observation | observation |
Timeline
- Start date
- 2024-03-10
- Primary completion
- 2029-03-10
- Completion
- 2029-03-10
- First posted
- 2024-03-15
- Last updated
- 2024-07-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06313567. Inclusion in this directory is not an endorsement.